In this study we describe the immunogenicity results from a subset of older people (N = 5187) who participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV versus TIV (Fluarix™) (ClinicalTrials.gov, NCT00753272). Participants received one dose of AS03-TIV or TIV in each study year and antibody titers against the vaccine strains were assessed using hemagglutination-inhibition (HI) assay at 21 d and 180 d post-vaccination in each vaccine group in the 2008/09 (Year 1) and 2009/10 (Year 2) influenza seasons. Manufacturing consistency of 3 lots of AS03-TIV for HI antibody responses in Year 1 was a co-primary objective. In a post-hoc analysis, a statistical regression model included 4830 subjects in whom immunogenicity and laboratory-confirmed attack rate data were available; the analysis was performed to assess HI antibody titers against A/H3N2 as a correlate of protection for laboratory-confirmed A/H3N2 influenza. AS03-TIV and TIV elicited strong HI antibody responses against each vaccine strain 21 d post-vaccination in both years. The manufacturing consistency of 3 lots of AS03-TIV was demonstrated. In both years and each vaccine group, HI antibody responses were lower for A/H1N1 than the other vaccine strains. Day 180 seroconversion rates (proportion with ≥4-fold increase in titer compared with pre-vaccination titer) in Year 1 in the AS03-TIV and TIV groups, respectively, were 87.7% and 74.1% for A/H3N2, 69.7% and 59.6% for influenza B, and 58.3% and 47.4% for A/H1N1. The post-hoc statistical model based on A/H3N2 attack rates and HI antibody titers estimated that a 4-fold increase in post-vaccination titers against A/H3N2 was associated with a 2-fold decrease in the odds of A/H3N2 infection.

b Centre for Vaccinology Ghent University and Ghent University Hospital Ghent Belgium

c Vaccination and Travel Medicine Centre Hradec Kralove Czech Republic; and 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Infectious Diseases Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Tlalpan C P México City México

e Institut für Tropenmedizin Tübingen Germany

f Inserm CIC 1417 and French Network of Clinical Investigation in Vaccinology Hôpital Cochin CIC Cochin Pasteur Paris France

g HSN Volunteer Association Chair in Geriatric Research Health Sciences North Research Institute Sudbury ON Canada

h Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht The Netherlands

i Institute of Statistics Biostatistics and Actuarial Sciences Université Catholique de Louvain Louvain la Neuve Belgium

j GSK Vaccines Wavre Belgium

Jeanne Marie Devaster MD GSK Vaccines Rixensart Belgium

k GSK Vaccines Rixensart Belgium

l GSK Vaccines Wavre Belgium

m Hôpital Bichat Claude Bernard GH BICHAT Paris cedex 18 France; Inserm CIC 007 for the French Network of Clinical Investigation in Vaccinology Paris Cedex 18 France

o Carolina Pharmaceutical Research Spartanburg South Carolina United States

p CHRU de Montpellier Hôpital Saint Eloi Montpellier France; Inserm CIC 1001 for the French Network of Clinical Investigation in Vaccinology Montpellier France

q Q and T Research Sherbrooke Sherbrooke QC Canada

r Department of Family Medicine Taipei Veterans General Hospital Taipei Taiwan; National Yang Ming University School of Medicine Taipei Taiwan

s Queen Elizabeth Health Sciences Centre Dalhousie University PCIRN NACI CCfV CAIRE QEII HSC VG Site Infectious Diseases Halifax Nova Scotia Canada

t GGD Rotterdam Rijnmond Rotterdam The Netherlands

u GSK Vaccines King of Prussia PA USA

University of Rochester Medical Center Rochester General Hospital Rochester NY USA

v GSK Vaccines Wavre Belgium

Zobrazit více v PubMed

McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23(Suppl 1):S10-25 PubMed

McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J Infect Dis 2008; 198:632-4; PMID:18652548; http://dx.doi.org/ 10.1086/590435 PubMed DOI

Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet (London, England) 2005; 366:1165-74; PMID:16198765; http://dx.doi.org/ 10.1016/S0140-6736(05)67339-4 PubMed DOI

Arakane R, Annaka R, Takahama A, Ishida K, Yoshiike M, Nakayama T, Takeshita F. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study. Vaccine 2015; 33:6650-8; PMID:26519549; http://dx.doi.org/ 10.1016/j.vaccine.2015.10.088 PubMed DOI

DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013; 31:861-6; PMID:23261045; http://dx.doi.org/ 10.1016/j.vaccine.2012.12.013 PubMed DOI

Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014; 32:5027-34; PMID:25045825; http://dx.doi.org/ 10.1016/j.vaccine.2014.07.013 PubMed DOI

Rumke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, et al.. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88; PMID:18407382; http://dx.doi.org/ 10.1016/j.vaccine.2008.02.068 PubMed DOI

Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V. Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults >/=65 years of age: a randomized, controlled, phase II trial. Vaccine 2014; 32:2507-17; PMID:24120672; http://dx.doi.org/ 10.1016/j.vaccine.2013.09.074 PubMed DOI

DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al.. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Eng J Med 2014; 371:635-45; PMID:25119609; http://dx.doi.org/ 10.1056/NEJMoa1315727 PubMed DOI

McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, et al.. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485-96; PMID:23518156; http://dx.doi.org/ 10.1016/S1473-3099(13)70046-X PubMed DOI

European Medicines Agency Guidance on influenza vaccines. EMA/CHMP/VWP/457259/2014, July 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170300.pdf

Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363-9; PMID:23413420; http://dx.doi.org/ 10.1093/cid/cit060 PubMed DOI PMC

Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 2015; 211:1519-28; PMID:25416812; http://dx.doi.org/ 10.1093/infdis/jiu650 PubMed DOI PMC

Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, et al.. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27; PMID:24235265; http://dx.doi.org/ 10.1093/cid/cit736 PubMed DOI PMC

Sullivan SG, Kelly H. Stratified estimates of influenza vaccine effectiveness by prior vaccination: caution required. Clin Infect Dis 2013; 57:474-6; PMID:23619811; http://dx.doi.org/ 10.1093/cid/cit255 PubMed DOI

Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40; PMID:15367555; http://dx.doi.org/ 10.1001/jama.292.11.1333 PubMed DOI

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/ 10.1001/jama.289.2.179 PubMed DOI

Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet (London, England) 2001; 358:1410-6; PMID:11705487; http://dx.doi.org/ 10.1016/S0140-6736(01)06528-X PubMed DOI

Durviaux S, Treanor J, Beran J, Duval X, Esen M, Feldman G, Frey SE, Launay O, Leroux-Roels G, McElhaney JE, et al.. Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial. Clin Vaccine Immunol 2014; 21:271-9; PMID:24371255; http://dx.doi.org/ 10.1128/CVI.00544-13 PubMed DOI PMC

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediat Infect Dis J 2011; 30:1081-5; http://dx.doi.org/ 10.1097/INF.0b013e3182367662 PubMed DOI

Gravenstein S, Drinka P, Duthie EH, Miller BA, Brown CS, Hensley M, Circo R, Langer E, Ershler WB. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am G S 1994; 42:245-51; http://dx.doi.org/ 10.1111/j.1532-5415.1994.tb01746.x PubMed DOI

McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol (Baltimore, Md : 1950) 2006; 176:6333-9; http://dx.doi.org/ 10.4049/jimmunol.176.10.6333 PubMed DOI

Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010; 28:6145-51; PMID:20646987; http://dx.doi.org/ 10.1016/j.vaccine.2010.07.036 PubMed DOI PMC

Hobson D, Curry R, Beare A, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70(4):767-77; PMID:4509641; http://dx.doi.org/ 10.1017/S0022172400022610 PubMed DOI PMC

Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; PMID:20210985; http://dx.doi.org/ 10.1186/1471-2288-10-18 PubMed DOI PMC

Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) 2011; 377:751-9; PMID:21329971; http://dx.doi.org/ 10.1016/S0140-6736(10)62228-3 PubMed DOI

Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004; 190:11-9; PMID:15195238; http://dx.doi.org/ 10.1086/421121 PubMed DOI

Hehme N, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69; http://dx.doi.org/ 10.2165/00044011-200222110-00004 DOI

Zhou X, McElhaney JE. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 2011; 29:2169-77; PMID:21353149; http://dx.doi.org/ 10.1016/j.vaccine.2010.12.029 PubMed DOI PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00753272